RLS GLOBAL AB (PUBL) INTERIM REPORT, Q2, 2020

APRIL 1[st] - JUNE 30[th] · Net sales amounted to TSEK 739 (TSEK 464) · Earnings before interest and taxes (EBIT) amounted to MSEK -5,6 (MSEK -5,8) · Earnings per share before dilution at SEK -0,09 (SEK-0,02) · Cash flow from operating activities amounted to MSEK -5,5 (MSEK-6,3) · Liquid assets at the end of…

Read more

RLS clinical trial - ChloraSolv01 – is completed and the result is to be analyzed

RLS Global is pleased to announce that the database for ChloraSolv01 is closed and RLS has received the first statistical report and results. ChloraSolv01 is a pilot study in which the patient with chronic ulcers on the lower leg or foot is treated with ChloraSolv for five weeks. The study endpoints include for example the…

Read more

RLS Global AB has signed an agreement with Region Stockholm and Gotland for ChloraSolv®

RLS Global AB is pleased to inform that ChloraSolv is awarded on the current tender agreement in Region Stockholm and Gotland. The agreement is effective August 15[th], 2020. The clinical evaluation has been very positive and ChloraSolv is now available to all healthcare providers in the region such as inpatient- and outpatient care, primary care,…

Read more

Increased interest in CariSolv due to the Corona pandemic

One consequence of the Corona pandemic is that the dental industry is facing a major shift in terms of caries treatment. Traditional treatment of caries attacks is done with drilling and repair. In connection with drilling in the tooth, aerosol is formed which radically increases the spread of infection during treatment. The dental industry is…

Read more

RLS GLOBAL AB (publ) INTERIM REPORT, Q1, 2020

JANUARY 1[st] - MARCH 31[st] · Net sales amounted to TSEK 374 (260 TSEK) · The operating loss for the period was MSEK -3.9 (-5.7 MSEK) · Earnings per share after dilution at SEK -0.06 (-0.04) · Cash flow from operating activities amounted to MSEK -4.2 (-5.5 MSEK) · Equity ratio was 92 percent (84…

Read more

RLS Global (publ) change Certified Adviser to Redeye AB

RLS Global AB announces today that the company will change Certified Adviser from Erik Penser Bank to Redeye AB. The transition will take place as of April 1[st], 2020. The background is that RLS will gather all advice with Redeye AB.

Read more

ChloraSolv is awarded on wound care tender in Region Kalmar Country Council and its municipalities

During the fall of 2019, RLS Global has worked intensively on the Swedish market with the aim to establish ChloraSolv as a product in the Swedish regions. In parallel, RLS has worked in close collaboration with OneMed to penetrate the market (municipalities and regions) where OneMed has agreements. As RLS has communicated in the past,…

Read more

RLS Global continues to develop its Wound Care business area and sells off the dental care portfolio

RLS Global’s strategy is to ensure a strong market penetration for ChloraSolv together with regional/global partnerships. ChloraSolv is based on a unique buffered hypochlorite technology with documented clinical results within Advanced Wound Care. During 2020, RLS will initiate pre-clinical activities with the aim of broadening the product portfolio within new clinical areas. New clinical indications…

Read more

RLS Global AB (publ) Year-end Report, 2019

October 1st - December 31st • Net sales amounted to kSEK 54 (1,131) • The operating loss for the period was MSEK -8.9 (-5.9) • Earnings per share after dilution at SEK -0.15 (-0.10) • Cash flow from operating activities amounted to MSEK -5.7 (-5.0) • Cash and cash equivalents amounted to MSEK 41.8 (22.6)

Read more

All patients enrolled for ChloraSolv01

RLS Global is pleased to announce that all patients are included in the study ChloraSolv 01, which has been performed on nine sites in Sweden. The inclusion criteria for the study are chronic wounds below the knee. The aim with the study is to obtain clinical data to regulatory extend the indication for use (diabetic…

Read more

RLS Global AB received its first order of ChloraSolv for clinical use

During the autumn of 2019, RLS Global focused on the Swedish market with the aim to get ChloraSolv established as a standard product in the regions. In parallel, RLS has worked in close collaboration with OneMed to penetrate the market in municipalities and regions there OneMed has supplier agreements. RLS Global also has ongoing dialogue with international players…

Read more

RLS GLOBAL AB (PUBL) Interim Report, January - September, 2019

July 1st - September 30th · Net sales amounted to SEK 0.2 million (1.0) · Earnings before interest and taxes (EBIT) amounted to SEK -6,1 million (-4,9) · Earnings per share before dilution at SEK -0,11 (-0,08) · Cash flow from operating activities amounted to SEK -7,4 million (-5,8) · Liquid assets at the end…

Read more

The new Shareholder list at RLS Global AB

RLS Global AB completed a directed new share issue raising proceeds of SEK 50 million as of 25th of September. It is very encouraging that RLS has engaged national- and international institutions to establish a long-term foundation for the company, says Karin Fischer, CEO RLS Global. The new shareholder list can be found at RLS…

Read more

RLS Global completes a directed new share issue of 7,520,000 shares, raising proceeds of SEK 50 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA, THE "UNITED STATES"), AUSTRALIA, CANADA,  HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR…

Read more

RLS Global announces intention of a directed new share issue of shares

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA, THE "UNITED STATES"), AUSTRALIA, CANADA,  HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR…

Read more

RLS Global signs agreement with OneMed AB

OneMed is one of the Nordic Countries largest distributors within medical technology providing services, support systems and products to the healthcare sector. RLS Global AB has signed a cooperation agreement with OneMed AB who will act as a distributor for ChloraSolv to address the municipalities and county councils with whom they have agreements with for…

Read more

Settlement with Karin Bergqvist

Settlement with Karin Bergqvist

Read more

RLS Global AB (PUBL) - Annual Report 2018

RLS Global AB (PUBL) - Annual Report 2018

Read more

ChloraSolv receives CE marking and is cleared for commercial launch in EU

Gothenburg, Sweden, April 10th, 2019 – RLS Global AB announces that ChloraSolv, its wound care product targeting diabetic foot ulcers, has successfully obtained a CE marking based on confirmation from Lloyd’s Register, acting as Notified Body, and is therefore cleared in 32 European countries for commercialization.

Read more

Year-end report 2018

Intensified work with ChloraSolv.

Read more